"C\u00EDlen\u00E1 \u2013 biologick\u00E1 l\u00E9\u010Dba karcinomu ovaria"@cs . "C\u00EDlen\u00E1 \u2013 biologick\u00E1 l\u00E9\u010Dba karcinomu ovaria" . "15" . "1"^^ . . . "190405" . "1"^^ . "C\u00EDlen\u00E1 \u2013 biologick\u00E1 l\u00E9\u010Dba karcinomu ovaria"@cs . . . "Epiteli\u00E1ln\u00ED ovari\u00E1ln\u00ED karcinom je druhou nej\u010Dast\u011Bj\u0161\u00ED gynekologickou malignitou a m\u00E1 mezi gynekologick\u00FDmi n\u00E1dory nejvy\u0161\u0161\u00ED \u00FAmrtnost. Z\u00E1kladn\u00ED l\u00E9\u010Dba obsahuje chirurgick\u00FD v\u00FDkon a chemoterapii na platinov\u00E9 b\u00E1zi. U v\u011Bt\u0161iny \u017Een s pokro\u010Dil\u00FDm onemocn\u011Bn\u00EDm v\u010Detn\u011B t\u011Bch, kter\u00E9 dos\u00E1hly kompletn\u00ED l\u00E9\u010Debn\u00E9 odpov\u011Bdi, dojde k relapsu nemoci. V sou\u010Dasn\u00E9 dob\u011B je vyv\u00EDjeno cel\u00E9 spektrum nov\u00FDch l\u00E1tek k l\u00E9\u010Db\u011B ovari\u00E1ln\u00EDho karcinomu. Mnoho z nich je zac\u00EDleno na angiogenezi \u2013 v\u00FDvoj nov\u00FDch c\u00E9v a lymfatik. Angiogeneze je nezbytn\u011B nutn\u00E1 pro v\u00FDvoj a r\u016Fst solidn\u00EDch tumor\u016F. V posledn\u00EDch letech bylo objeveno mnoho specifick\u00FDch nov\u00FDch inhibitor\u016F angiogeneze. Jde o druh terapie, kter\u00E1 pomoc\u00ED monoklon\u00E1ln\u00EDch protil\u00E1tek nebo jin\u00FDch \u010D\u00E1stic vyhled\u00E1v\u00E1 a napad\u00E1 n\u00E1dorov\u00E9 bu\u0148ky. Obzvl\u00E1\u0161\u0165 slibn\u00FDm c\u00EDlem se jev\u00ED vaskul\u00E1rn\u00ED endoteli\u00E1ln\u00ED r\u016Fstov\u00FD faktor. Velk\u00E9ho pokroku v c\u00EDlen\u00E9 l\u00E9\u010Db\u011B karcinomu ovaria bylo dosa\u017Eeno pou\u017Eit\u00EDm bevacizumabu. V sou\u010Dasnosti je c\u00EDlen\u00E1 biologick\u00E1 l\u00E9\u010Dba jednou z hlavn\u00EDch priorit protin\u00E1dorov\u00E9ho v\u00FDzkumu." . "ovarian carcinoma; targeted therapy; bevacizumab; tyrosinkinase inhibitors"@en . "4"^^ . . . "Targeted - biological treatment of ovarian cancer"@en . "[B6354EA1BAB2]" . "Epiteli\u00E1ln\u00ED ovari\u00E1ln\u00ED karcinom je druhou nej\u010Dast\u011Bj\u0161\u00ED gynekologickou malignitou a m\u00E1 mezi gynekologick\u00FDmi n\u00E1dory nejvy\u0161\u0161\u00ED \u00FAmrtnost. Z\u00E1kladn\u00ED l\u00E9\u010Dba obsahuje chirurgick\u00FD v\u00FDkon a chemoterapii na platinov\u00E9 b\u00E1zi. U v\u011Bt\u0161iny \u017Een s pokro\u010Dil\u00FDm onemocn\u011Bn\u00EDm v\u010Detn\u011B t\u011Bch, kter\u00E9 dos\u00E1hly kompletn\u00ED l\u00E9\u010Debn\u00E9 odpov\u011Bdi, dojde k relapsu nemoci. V sou\u010Dasn\u00E9 dob\u011B je vyv\u00EDjeno cel\u00E9 spektrum nov\u00FDch l\u00E1tek k l\u00E9\u010Db\u011B ovari\u00E1ln\u00EDho karcinomu. Mnoho z nich je zac\u00EDleno na angiogenezi \u2013 v\u00FDvoj nov\u00FDch c\u00E9v a lymfatik. Angiogeneze je nezbytn\u011B nutn\u00E1 pro v\u00FDvoj a r\u016Fst solidn\u00EDch tumor\u016F. V posledn\u00EDch letech bylo objeveno mnoho specifick\u00FDch nov\u00FDch inhibitor\u016F angiogeneze. Jde o druh terapie, kter\u00E1 pomoc\u00ED monoklon\u00E1ln\u00EDch protil\u00E1tek nebo jin\u00FDch \u010D\u00E1stic vyhled\u00E1v\u00E1 a napad\u00E1 n\u00E1dorov\u00E9 bu\u0148ky. Obzvl\u00E1\u0161\u0165 slibn\u00FDm c\u00EDlem se jev\u00ED vaskul\u00E1rn\u00ED endoteli\u00E1ln\u00ED r\u016Fstov\u00FD faktor. Velk\u00E9ho pokroku v c\u00EDlen\u00E9 l\u00E9\u010Db\u011B karcinomu ovaria bylo dosa\u017Eeno pou\u017Eit\u00EDm bevacizumabu. V sou\u010Dasnosti je c\u00EDlen\u00E1 biologick\u00E1 l\u00E9\u010Dba jednou z hlavn\u00EDch priorit protin\u00E1dorov\u00E9ho v\u00FDzkumu."@cs . "P(ED2.1.00/03.0101), Z(MZ0MOU2005)" . . . "RIV/00209805:_____/11:#0000151!RIV12-MSM-00209805" . . "C\u00EDlen\u00E1 \u2013 biologick\u00E1 l\u00E9\u010Dba karcinomu ovaria" . "1801-8750" . . "RIV/00209805:_____/11:#0000151" . "http://www.prolekare.cz/prakticka-gynekologie-clanek/cilena-biologicka-lecba-karcinomu-ovaria-36352?search=" . . . "Praktick\u00E1 gynekologie" . "3-4" . . "Targeted - biological treatment of ovarian cancer"@en . . "Epithelial ovarian cancer is the second most common gynecological malignancy and is among gynecological tumors, the highest mortality. Basic treatment includes surgery and platinum-based chemotherapy. For most women with advanced disease, including those that have achieved a complete response, there is a relapse of the disease. Currently, developed a variety of new agents for the treatment of ovarian cancer. Many of them are targeted at angiogenesis - the development of new blood vessels and lymphatics. Angiogenesis is essential for the development and growth of solid tumors. In recent years, discovered many new specific inhibitors of angiogenesis. It is a kind of therapy that uses monoclonal antibodies or other particle searches and infects the tumor cells. Especially promising seems to vascular endothelial growth factor. Great progress in targeted therapy of ovarian cancer has been achieved by the use of bevacizumab. At present, targeted biological therapy a high priority for anticancer research."@en . "CZ - \u010Cesk\u00E1 republika" . . . . . . "Chovanec, Josef" .